Digestive Diseases
| Ulcerative colitis
Digestive Diseases
Ulcerative colitis
The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 QUASAR induction study
book_2
Source:
UEG Week 2023 - Oral session
calendar_today
Published on Medfyle:
November 2023
import_contacts
5
min
In this medfyle
The Phase 3 QUASAR induction study evaluated the efficacy and safety of guselkumab in patients with moderately to severely active UC. These induction study results report guselkumab efficacy and safety outcomes and demonstrate clinically meaningful improvements across a range of symptomatic and histo-endoscopic endpoints at Week 12.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the UEG Week 2023.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content.
©2023 Infomedica-Medfyle. All rights reserved.
